HEK293-VEGF-TM Cells
USD 1,600.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Información general
| Descripción | Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. HEK293-VEGF-TM cells are human embryonic kidney 293 (HEK293) cells engineered to stably express a membrane-tethered form of vascular endothelial growth factor (VEGF), commonly designed to present VEGF at the cell surface through fusion with a transmembrane domain. Unlike soluble VEGF isoforms that are secreted into the extracellular environment, VEGF-TM constructs enable localized and sustained presentation of VEGF ligands on the plasma membrane, facilitating controlled investigation of VEGF receptor interactions and cell-cell signaling mechanisms. These engineered models are useful for studying angiogenic signaling pathways mediated primarily through VEGFR1 (FLT1) and VEGFR2 (KDR), which regulate endothelial proliferation, migration, vascular permeability, and neovascularization. HEK293-VEGF-TM cells are widely used in angiogenesis research and therapeutic development for characterization of VEGF-targeted antibodies, receptor traps, anti-angiogenic biologics, and engineered immune cell therapies. The membrane-anchored VEGF presentation enables quantitative assessment of receptor binding, ligand accessibility, antibody blockade, receptor clustering, and cell-contact-dependent signaling events. These cells are particularly valuable in flow cytometry-based binding assays, co-culture systems, reporter assays, and high-throughput screening platforms evaluating VEGF/VEGFR pathway inhibition. In addition, HEK293-VEGF-TM models can support studies examining synapse formation and target recognition by VEGF-directed CAR-T cells or bispecific antibody platforms. |
|---|---|
| Organismo | Human |
| Tejido | Fetal Kidney |
| Enfermedad | Transformed/immortalized; non-tumorigenic (HEK293 background) |
| Aplicaciones | Transmembrane VEGF (VEGF-TM) research; anti-VEGF antibody development; tumor angiogenesis studies; ADCC/CDC assays; flow cytometry; oncology and ophthalmology research |
Características
| Edad | Fetus |
|---|---|
| Género | Female |
| Morfología | Epithelial-like |
| Tipo de célula | Epithelial cells |
| Propiedades de crecimiento | Monolayer, adherent |
Datos normativos
| Referencia | HEK293-VEGF-TM (Cytion catalog number 305991) |
|---|---|
| Nivel de bioseguridad | 1 |
| NCBI_TaxID | 9606 |
| N.º de acceso de Cellosaurus | CVCL_6G30 |
| Estado de los OGM | GMO-S1: This HEK293 cell line contains a transmembrane VEGF (VEGF-TM) expression construct for cell-surface VEGF studies and anti-angiogenic therapy development. This classification applies only within Germany and may differ elsewhere. |
Datos biomoleculares
| Receptores expresados | VEGF-TM |
|---|
Manejo
| Medio de cultivo | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suplementos | Supplement the medium with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. |
| Reactivo de disociación | Trypsin-EDTA |
| Tiempo de duplicación | approx. 24-36 hours |
| Subcultivo | For routine adherent cell culture: Aspirate the old culture medium from the adherent cells, and wash them with PBS to remove any remaining medium. After aspirating the PBS, add the appropriate volume of Trypsin/EDTA solution based on the culture vessel size (e.g., 1 ml for a T25 flask, 3 ml for a T75 flask) and incubate at room temperature or 37°C until the cells detach (5-10 minutes). Monitor detachment under a microscope, and gently tap the vessel if necessary to release the cells. Once detached, add complete medium to inactivate the Trypsin/EDTA, gently resuspend the cells, and transfer an aliquot of the cell suspension into a new culture vessel containing fresh medium. Place the vessel in an incubator set to 37°C with 5% CO2, and change the medium every 2-3 days. |
| Relación de división | 1 to 5 |
| Densidad de siembra | 2 to 4 x 104 cells/cm2 |
| Renovación de fluidos | 2 to 3 times per week |
| Recuperación tras el deshielo | After thawing, split the cells at a ratio of 1:2 to 1:3 in T25 flasks and allow the cells to recover from the freezing process and to adhere for at least 24 hours. For best attachment and viability after thawing the cells, we recommend using Collagen-coated flasks or plates for the initial seeding after cryo-recovery. Collagen coating is not required for subsequent routine culture of the cells. |
| Medio de congelación | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Descongelación y cultivo de células |
|
| Atmósfera de incubación | 37°C, 5% CO2, humidified atmosphere. |
| Condiciones de envío | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condiciones de almacenamiento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Control de calidad y análisis molecular
| Esterilidad | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|